All In MedTech

Device Trial Radar · NCT06867705

Randomized Controlled Trial of Remote Symptoms Monitoring With Resilience PRO Compared to Care As Usual Only

Digital Monitoring With Patient-Reported Outcomes in Cancer Care: A Randomized Controlled Trial RC - 102 (Resilience Care - 102)

Last checked: Nov 20, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,458 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,458

Planned (sponsor's estimate)

Start

Apr 1, 2025

Primary completion

Jan 2027

Study completion Dec 2029

Sponsor

Lead sponsor
ResilienceNot on our public-company list
Sponsor type
Industry
Collaborators
UNICANCER; Sanoia
First posted
Mar 10, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Supportive care
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if Resilience PRO, a digital solution performing remote symptoms monitoring, can improve the quality of life of patients with a diagnosis of cancer receiving systemic anticancer treatment. The main question it aims to answer is: \- Do patients with a diagnosis of cancer receiving systemic anticancer therapy and using Resilience PRO have an improved quality of life? Researchers will compare patients using Resilience PRO plus care as usual to patients receiving care as usual only. Participants in the intervention arm will use Resilience PRO, a mobile phone application regularly asking participants about their symptoms. For clinically important symptoms, an alert is sent to the care team that can incorporate that information to timely adjust the care of the participants. Participants both in the control arm and in the intervention arm will further receive care as usual.

Conditions

  • Cancer

Interventions

  • Resilience PRODevice

    The patient will use Resilience PRO remote symptoms monitoring.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Health-Related quality of lifeTime frame: 3 months

Locations

36 sites in 2 countries. Site status is shown where the registry gives one.

  • Hôpital Privé de Provence

    Aix-en-Provence, France · Recruiting

  • Centre Hospitalier du Pays d'Aix - Centre Hospitalier Intercommunal Aix-Pertuis

    Aix-en-Provence, France · Recruiting

  • Centre Hospitalier Henri Mondor-Aurillac

    Aurillac, France · Recruiting

33 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.